ADLM 2024 Biotest Successful Conclusion

The highly anticipated 76th ADLM Biotest 2024 (formerly known as AACC) was held from July 28 to August 1, 2024 at McCormick Place Exhibition Center in Chicago, USA. The exhibition attracted more than 2,500 top exhibitors from more than 900 countries around the world, focusing on the display of the latest world's clinical laboratory testing technology equipment and in vitro diagnostic products. ADLM exhibition is not only a place where industry elites meet, but also a window to display the innovative achievements, which builds an excellent platform for the communication and cooperation in the field of global clinical testing.

Innovation leads the future, technology drives development

In this year's exhibition, Biotest, with its innovative spirit and excellent technology, launched a series of remarkable new products, technologies and upgraded products, including IM Reader, Beverage Drug Test, Harm Reduction Test, SalivaTracer Drug Screen Test, PowderTracer Drug Screen Test, and other new and upgraded products, including IM Reader, Beverage Drug Test. Harm Reduction Test, SalivaTracer Drug Screen Test, PowderTracer Drug Screen Test, Immunochromatography Rapid Test, Active Microfluidic Immunology Platform, N.N-Dimethyltryptamine (DMT) Drug Test, and many more. These new products are characterized by cutting-edge technology and These new products, with their cutting-edge technology and excellent performance, attracted the attention of many visitors and became one of the highlights of the exhibition. Especially, the newly developed microfluidic platform testing technology launched by the company during the exhibition, the core of which lies in its biochip design, making it possible to further improve the sensitivity and speed of the test, while also being able to achieve multi-item joint testing, which is widely praised and concerned by the industry for its unique technological advantages.

Biotest, make an all-out effort

In this ADLM medical exhibition, Biotest, together with its US subsidiary ADVIN BIOTECH, sent a strong exhibition team. Through on-site communication with customers, we not only gained a deep understanding of the real needs and trends of the international market, especially the North American and Latin American markets, but also collected valuable suggestions from customers on new product development. In order to further expand the overseas market, we have carefully planned and launched diagnostic business that meets the characteristics of the target market according to the medical needs, economic level and cultural background of different countries and regions, so as to satisfy the diversified needs of our customers.

Global vision, local strategy

In this era of global innovation, communication and cooperation, Biotest's global journey is in full swing, Biotest will take this exhibition as an opportunity to continue to firmly implement the ADVIN BIOTECH-based U.S. localization strategy, to expand and strengthen the North American market, and then radiate to Latin America, Europe and other markets, new era, new opportunities, Biotest will always insist on In the new era and new opportunities, Biotest will always adhere to the concept of "scientific and technological innovation, quality-oriented", and is committed to promoting the development and progress of the global bio-detection technology, and contributing to the cause of human health.